MILANO VINCENT — SEC insider filings
SEC reporting owner CIK 1187159. 40 insider filings on record with FilingPulse; latest filed 2026-09-02.
Transaction summary — filings shown
Covers all 40 filings on record, filed 2020-12-22 to 2026-09-02. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 22,500 shares, $185,175 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 4 legs across 4 filings — 46,402 shares, $186,450 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 56.
- Largest priced transaction: sale of 37,169 shares @ $4.32 ($160,525) in Aceragen, Inc., filed 2020-12-22.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Aceragen, Inc. (ACGN) | Director | 8 | — | 4 legs · 46,402 sh · $186,450 | 6 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | Director | 25 | 2 legs · 22,500 sh · $185,175 | — | 28 |
| Aclaris Therapeutics, Inc. (ACRS) | Director | 7 | — | — | 22 |
Insider filings — MILANO VINCENT
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-02 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 1,159 @ $9.70 | EDGAR |
| 2026-06-15 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 15,294 @ $0 · Grant/award (A): 33,540 (derivative) @ $0 | EDGAR |
| 2026-06-08 | 4 | Aclaris Therapeutics, Inc. (ACRS) | Option exercise (M): 11,580 · Grant/award (A): 42,350 (derivative) @ $0 · Grant/award (A): 10,987 (derivative) @ $0 · Option exercise (M): 11,580 (derivative) @ $0 | EDGAR |
| 2026-06-02 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 1,122 @ $8.91 | EDGAR |
| 2026-03-03 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 848 @ $8.75 | EDGAR |
| 2025-12-02 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 783 @ $7.18 | EDGAR |
| 2025-09-03 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 676 @ $8.31 | EDGAR |
| 2025-06-16 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 12,500 @ $0 · Grant/award (A): 27,181 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | Aclaris Therapeutics, Inc. (ACRS) | Option exercise (M): 4,793 · Grant/award (A): 42,350 (derivative) @ $0 · Grant/award (A): 11,580 (derivative) @ $0 · Option exercise (M): 4,793 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 523 @ $10.75 | EDGAR |
| 2025-03-04 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 653 @ $8.61 | EDGAR |
| 2024-12-02 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 750 @ $7.50 | EDGAR |
| 2024-09-03 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 647 @ $8.69 | EDGAR |
| 2024-06-14 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 6,820 @ $0 · Grant/award (A): 49,933 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | Aclaris Therapeutics, Inc. (ACRS) | Grant/award (A): 15,750 (derivative) @ $0 · Grant/award (A): 4,793 (derivative) @ $0 | EDGAR |
| 2024-06-04 | 4 | Aclaris Therapeutics, Inc. (ACRS) | Option exercise (M): 4,660 · Option exercise (M): 4,660 (derivative) @ $0 | EDGAR |
| 2024-06-03 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 870 @ $6.46 | EDGAR |
| 2024-05-22 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Purchase (P): 15,000 @ $6.25 | EDGAR |
| 2024-03-04 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 999 @ $5.63 | EDGAR |
| 2023-12-01 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 956 @ $5.88 | EDGAR |
| 2023-09-05 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 791 @ $7.11 | EDGAR |
| 2023-08-11 | 4 | Aceragen, Inc. (ACGN) | Sale (S): 3,283 @ $0.53 | EDGAR |
| 2023-06-15 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 16,745 @ $0 · Grant/award (A): 39,072 (derivative) @ $0 | EDGAR |
| 2023-06-05 | 4 | Aclaris Therapeutics, Inc. (ACRS) | Option exercise (M): 4,507 · Grant/award (A): 15,750 (derivative) @ $0 · Grant/award (A): 4,660 (derivative) @ $0 · Option exercise (M): 4,507 (derivative) @ $0 | EDGAR |
| 2023-06-02 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 680 @ $8.27 | EDGAR |
| 2023-03-02 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 635 @ $8.85 | EDGAR |
| 2022-12-02 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 421 @ $13.36 | EDGAR |
| 2022-09-02 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 404 @ $13.90 | EDGAR |
| 2022-07-07 | 4 | IDERA PHARMACEUTICALS, INC. (IDRA) | Grant/award (A): 124,000 (derivative) @ $0 | EDGAR |
| 2022-06-09 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 12,866 @ $0 · Grant/award (A): 30,022 (derivative) @ $0 | EDGAR |
| 2022-06-06 | 4 | Aclaris Therapeutics, Inc. (ACRS) | Option exercise (M): 3,356 · Grant/award (A): 15,750 (derivative) @ $0 · Grant/award (A): 4,507 (derivative) @ $0 · Option exercise (M): 3,356 (derivative) @ $0 | EDGAR |
| 2022-04-04 | 4 | IDERA PHARMACEUTICALS, INC. (IDRA) | Grant/award (A): 99,000 (derivative) @ $0 | EDGAR |
| 2022-01-26 | 4 | IDERA PHARMACEUTICALS, INC. (IDRA) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2021-11-24 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Purchase (P): 7,500 @ $12.19 | EDGAR |
| 2021-07-28 | 4 | BIOCRYST PHARMACEUTICALS INC (BCRX) | Grant/award (A): 66,667 (derivative) @ $0 | EDGAR |
| 2021-07-12 | 4 | IDERA PHARMACEUTICALS, INC. (IDRA) | Grant/award (A): 124,000 (derivative) @ $0 | EDGAR |
| 2021-06-04 | 4 | Aclaris Therapeutics, Inc. (ACRS) | Grant/award (A): 12,250 (derivative) @ $0 · Grant/award (A): 3,356 (derivative) @ $0 | EDGAR |
| 2021-01-12 | 4 | IDERA PHARMACEUTICALS, INC. (IDRA) | Sale (S): 3,210 @ $4.20 · Grant/award (A): 95,000 (derivative) @ $0 | EDGAR |
| 2021-01-11 | 4 | IDERA PHARMACEUTICALS, INC. (IDRA) | Sale (S): 2,740 @ $3.91 | EDGAR |
| 2020-12-22 | 4 | IDERA PHARMACEUTICALS, INC. (IDRA) | Grant/award (A): 128,170 @ $0 · Sale (S): 37,169 @ $4.32 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-12-17 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1187159 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs